New AstraZeneca COVID-19 Vaccine data further support its use as third dose booster

New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha and Gamma variants following third dose booster with AstraZeneca COVID-19 Vaccine; Additional analysis showed increased antibody response to Omicron after a third dose.

AstraZeneca’s COVID-19 vaccine significantly boosted antibody levels against Omicron

Neutralising antibody levels against Omicron following a third dose boost of AstraZeneca’s COVID-19 vaccine were broadly similar to levels achieved after two doses against the Delta variant

AstraZeneca COVID-19 Vaccine and mRNA COVID-19 vaccines showed similar and favorable safety profiles in a population-based cohort study of over a million people

Safety profiles of AstraZeneca’s COVID-19 Vaccine, and the mRNA-based vaccine were similar and overall favorable.